---
theme: academic
layout: cover
class: text-white
coverAuthor: beau hilton 
coverAuthorUrl: https://www.beauhilton.com
coverDate: "2023-03-31"
themeConfig:
  paginationX: r
  paginationY: t
  paginationPagesDisabled: [1]
title: Lower-Risk MDS
info: |
  # Lower-Risk MDS
  Case Conference 2023-03-31, [Beau Hilton](https://www.beauhilton.com)

---

# Lower-Risk MDS

---

# Case presentation

81M w CKD (b/l Cr 1.8), HFpEF (admitted 2x last year), AF (on apixaban), p/w hgb 10.1, MCV 99.

Feels fine overall, some DoE that is longstanding, doing well since last admission and diuresis.

No frequent infections. 

Doesn't have dentures, no OTC supps.


---

# Case presentation

## Labs

<v-clicks>

- hgb 10.1, MCV 99
- plt 132
- WBC 5.3, normal diff

- folate, B12 replete

- TSAT 19%

</v-clicks>

---

# Case presentation

Given 1g IV iron, seen back in 10wks, BMBx scheduled prophylactically

hgb 9.6, MCV 97

other counts unchanged


---

# Case presentation

## BMBx

<v-clicks>

- something
- something else

</v-clicks>

---

# Questions

- How do we risk-stratify MDS?
- What are the relative incidences of the risk strata?
- When do we intervene in lower-risk disease?
- What tools do we have?
- How do we sequence therapies?
- Can we impact prognosis?

---


# Epidemiology

<v-clicks>

- yearly incidence: 4/100,000<sup>1</sup>
- incidence increases with age:<sup>2</sup>
  - <40yo: 0.1/100,000
  - \>65yo: 25/100,000
  - 70-79yo: 30/100,000
  - \>80yo: 60/100,000
  - underreported: yearly incidence >65yo may be as high as 75/100,000<sup>3</sup>
- median age of dx: 70-75
- male predominance
  - 5.4/100,000 vs 2.9/100,000 in women
  - del(5q) more common in women (7:3)
- 75% are LR-MDS

</v-clicks>



<Footnotes separator>
  <Footnote :number=1><a href="https://beauhilton.com" rel="noreferrer" target="_blank">Sekeres</a></Footnote>
  <Footnote :number=2><a href="https://beauhilton.com" rel="noreferrer" target="_blank">Toprak</a></Footnote>
  <Footnote :number=3><a href="https://beauhilton.com" rel="noreferrer" target="_blank">de Witte 2020</a></Footnote>
</Footnotes>

---
layout: figure
figureUrl: ./images/ipssr-surv-aml.png
---
# Risk stratification


---

# Management

---
layout: index
indexEntries:
  - { title: "HemOnc.org entry", uri: "https://hemonc.org" }
  - { title: "NCCN Guidelines", uri: "https://www.nccn.org/professionals/physician_gls" }
  - { title: "PathologyOutline", uri: "https://www.pathologyoutlines.com" }
  - { title: "", uri: "" }
  - { title: "", uri: "" }
  - { title: "", uri: "" }
  - { title: "", uri: "" }
  - { title: "", uri: "" }
indexRedirectType: external
---

# Resources

---

# Bibliography

Use HTML export from Zotero. 
It's great. 
Looks kinda like the following 
(note I changed the text size with `text-sm` from WindiCSS.)

<div class="csl-bib-body text-sm" style="line-height: 1.35; margin-left: 2em; text-indent:-2em;">
  <div class="csl-entry">Al Subhi, Abdul Rahman, Veronica Boyle, and Marianne S. Elston. “Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years.” <i>Journal of the Endocrine Society</i> 6, no. 9 (September 1, 2022): bvac105. <a href="https://doi.org/10.1210/jendso/bvac105">https://doi.org/10.1210/jendso/bvac105</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1210%2Fjendso%2Fbvac105&amp;rft_id=info%3Apmid%2F35919261&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Systematic%20Review%3A%20Incidence%20of%20Pheochromocytoma%20and%20Paraganglioma%20Over%2070%20Years&amp;rft.jtitle=Journal%20of%20the%20Endocrine%20Society&amp;rft.stitle=J%20Endocr%20Soc&amp;rft.volume=6&amp;rft.issue=9&amp;rft.aufirst=Abdul%20Rahman&amp;rft.aulast=Al%20Subhi&amp;rft.au=Abdul%20Rahman%20Al%20Subhi&amp;rft.au=Veronica%20Boyle&amp;rft.au=Marianne%20S.%20Elston&amp;rft.date=2022-09-01&amp;rft.pages=bvac105&amp;rft.issn=2472-1972&amp;rft.language=eng"></span>
</div>

---
